Cefmenoxime: Difference between revisions
Jump to navigation
Jump to search
m Protected "Cefmenoxime": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
No edit summary |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{drugbox | {{drugbox | ||
| IUPAC_name = (6''R'',7''R'')-7-{[(2''E'')-2-(2-amino-1,3-thiazol-4-yl)-<br>2-methoxyimino-acetyl]amino}-3-[(1-methyltetrazol-<br>5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]<br>oct-2-ene-2-carboxylic acid | | IUPAC_name = (6''R'',7''R'')-7-{[(2''E'')-2-(2-amino-1,3-thiazol-4-yl)-<br>2-methoxyimino-acetyl]amino}-3-[(1-methyltetrazol-<br>5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]<br>oct-2-ene-2-carboxylic acid | ||
| image = Cefmenoxime.svg | | image = Cefmenoxime.svg.png | ||
| CAS_number = 65085-01-0 | | CAS_number = 65085-01-0 | ||
| ATC_prefix = J01 | | ATC_prefix = J01 | ||
| Line 24: | Line 24: | ||
| routes_of_administration = Intramuscular, [[Intravenous therapy|intravenous]] | | routes_of_administration = Intramuscular, [[Intravenous therapy|intravenous]] | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | {{SI}} | ||
{{ | {{CMG}} | ||
==Overview== | |||
'''Cefmenoxime''' is a third-generation [[cephalosporin]] [[antibiotic]]. | |||
==External links== | ==External links== | ||
* {{DiseasesDB|30892}} | * {{DiseasesDB|30892}} | ||
* {{cite journal | author = Yokota N, Koguchi M, Suzuki Y, Fukayama S, Ishihara R, Deguchi K, Oda S, Tanaka S, Nakane Y, Fukumoto T | title = Antibacterial activities of cefmenoxime against recent fresh clinical isolates from patients in sinusitis | journal = Jpn J Antibiot | volume = 48 | issue = 5 | pages = 602-9 | year = 1995 | id = PMID 7637194}} | * {{cite journal | author = Yokota N, Koguchi M, Suzuki Y, Fukayama S, Ishihara R, Deguchi K, Oda S, Tanaka S, Nakane Y, Fukumoto T | title = Antibacterial activities of cefmenoxime against recent fresh clinical isolates from patients in sinusitis | journal = Jpn J Antibiot | volume = 48 | issue = 5 | pages = 602-9 | year = 1995 | id = PMID 7637194}} | ||
* {{cite journal | author = Paladino J, Fell R | title = Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia. | journal = Ann Pharmacother | volume = 28 | issue = 3 | pages = 384-9 | year = 1994 | id = PMID 8193431}} | * {{cite journal | author = Paladino J, Fell R | title = Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia. | journal = Ann Pharmacother | volume = 28 | issue = 3 | pages = 384-9 | year = 1994 | id = PMID 8193431}} | ||
* {{cite journal | author = Duncker G, Reich U, Krausse R | title = Cefmenoxime in corneal organ culture. | journal = Ophthalmologica | volume = 208 | issue = 5 | pages = 262-6 | year = 1994 | id = PMID 7816419}} | * {{cite journal | author = Duncker G, Reich U, Krausse R | title = Cefmenoxime in corneal organ culture. | journal = Ophthalmologica | volume = 208 | issue = 5 | pages = 262-6 | year = 1994 | id = PMID 7816419}} | ||
| Line 43: | Line 42: | ||
[[Category:Tetrazoles]] | [[Category:Tetrazoles]] | ||
[[Category:Cephalosporin antibiotics]] | [[Category:Cephalosporin antibiotics]] | ||
[[Category:Drug]] | |||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 18:05, 8 April 2015
 | |
| Clinical data | |
|---|---|
| Routes of administration | Intramuscular, intravenous |
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | 100% (given IM) |
| Protein binding | 50% to 70% |
| Metabolism | Negligible |
| Elimination half-life | 1 hour |
| Excretion | Renal, unchanged |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C16H17N9O5S3 |
| Molar mass | 511.562 g/mol |
|
WikiDoc Resources for Cefmenoxime |
|
Articles |
|---|
|
Most recent articles on Cefmenoxime Most cited articles on Cefmenoxime |
|
Media |
|
Powerpoint slides on Cefmenoxime |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Cefmenoxime at Clinical Trials.gov Clinical Trials on Cefmenoxime at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Cefmenoxime
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Cefmenoxime Discussion groups on Cefmenoxime Patient Handouts on Cefmenoxime Directions to Hospitals Treating Cefmenoxime Risk calculators and risk factors for Cefmenoxime
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Cefmenoxime |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Cefmenoxime is a third-generation cephalosporin antibiotic.
External links
- Template:DiseasesDB
- Yokota N, Koguchi M, Suzuki Y, Fukayama S, Ishihara R, Deguchi K, Oda S, Tanaka S, Nakane Y, Fukumoto T (1995). "Antibacterial activities of cefmenoxime against recent fresh clinical isolates from patients in sinusitis". Jpn J Antibiot. 48 (5): 602–9. PMID 7637194.
- Paladino J, Fell R (1994). "Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia". Ann Pharmacother. 28 (3): 384–9. PMID 8193431.
- Duncker G, Reich U, Krausse R (1994). "Cefmenoxime in corneal organ culture". Ophthalmologica. 208 (5): 262–6. PMID 7816419.
Categories:
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- CS1 maint: Multiple names: authors list
- Thiazoles
- Tetrazoles
- Cephalosporin antibiotics
- Drug